Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 07, 2015 9:35 AM ET

Pharmaceuticals

Company Overview of Lycera Corp.

Company Overview

Lycera Corp., a biopharmaceutical company, discovers and develops oral immune modulators for the treatment of patients with autoimmune diseases and cancers. Its product pipeline includes LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease; oral RORgamma agonists for diverse applications in immune-oncology; and Rho kinase inhibitors, histone deacetylase 6 inhibitors, RORgt antagonists, and collaboration targets. Lycera Corp. was founded in 2006 and is headquartered in Ann Arbor, Michigan.

2800 Plymouth Road

NCRC

Building 26

Ann Arbor, MI 48109

United States

Founded in 2006

Phone:

734-233-3060

Key Executives for Lycera Corp.

Chief Executive Officer, President and Director
Age: 56
Co-Founder, Chief Scientific Officer and Director
Co-Owner
Senior Vice President of Corporate Development and Strategy
Senior Vice President of Biology
Compensation as of Fiscal Year 2015.

Lycera Corp. Key Developments

Lycera and Celgene Partner to Advance Development of Immune Modulators

Lycera has entered an exclusive strategic collaboration with Celgene to advance the development of its proprietary pipeline for cancer and immune-mediated diseases. The partnership will advance development of Lycera's novel pipeline, including first-in-class RORgamma agonists for cancer immunotherapy and clinical-stage candidate, LYC-30937, being studied for inflammatory bowel disease (IBD). As part of the deal, Lycera will provide an $82.5 million upfront cash payment, which comprises an exclusive option for Celgene to license Lycera's portfolio of ex-vivo RORgamma agonist compounds. The deal will also allow Lycera to receive near term payments of an additional $22.5 million associated with the ex-vivo licensing option rights. In addition, the deal provides Celgene exclusive rights to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones.

Lycera Begins Phase I Trial of LYC-30937 to Treat Inflammatory Bowel Disease

Lycera announced that the company has started a phase I clinical trial of LYC-30937, an oral gut-directed ATPase modulator, for the treatment of inflammatory bowel disease (IBD). Discovered and developed by Lycera based on technology licensed from the University of Michigan, LYC-30937 is designed to selectively induce cell death (apoptosis) in disease-causing immune cells, sparing normal cells. The company maintains full worldwide development and commercial rights of the product. In mid-2016, the company intends to begin clinical trials for its lead immune-oncology product candidate, an agonist of RORgamma, as well as an anti-fibrotic agent, a highly selective ROCK2 (rho-associated kinase II) inhibitor.

Lycera Corp to Present Preclinical Research from its Novel Cancer Immunotherapy Program at the 2015 American Association for Cancer Research Annual Meeting

Lycera Corp. announced that the company will present preclinical research from its novel cancer immunotherapy program at the American Association for Cancer Research (AACR) annual meeting, which will take place in Philadelphia, Pennsylvania, April 18-22, 2015. Abbreviated abstract summary: Agents that enhance activation or release suppression of the immune system could form the basis of new treatments for cancer. The receptor RORgamma modulates expression of genes involved in multiple anti-tumor mechanisms. Lycera's program to advance small molecule RORgamma agonists has demonstrated: Select immune cells (Th17 and Tc17) differentiated in the presence of RORgamma agonists exhibit decreased expression of inhibitory molecules, such as PD-1, and increased expression of costimulatory molecules. Th17 and Tc17 cells are reported to mediate potent and durable anti-cancer efficacy. In vitro activation of certain Tc17 cells with RORgamma agonists generates potent effector cells that control the growth of large EG7 tumors when transferred into a preclinical in vivo model. Tumor-infiltrating lymphocytes (TILs) from this model have enhanced survival and decreased PD-1 expression. Oral administration of RORgamma agonists in a preclinical in vivo model significantly inhibits the growth of established, subcutaneous MC38 colon carcinoma tumors. RORgamma agonists also inhibit growth of established, subcutaneous 4T1 mammary carcinoma tumors in an in vivo model. The abstract concluded that, as a transcription modulator, RORgamma agonists increase immune activation and decrease immune suppression. These activities translate into robust anti-tumor effects in syngeneic tumor models and represent a promising approach for the treatment of cancer.

Similar Private Companies By Industry

Company Name Region
Araxes Pharma, LLC United States
Applied Therapeutics, Inc. United States
Aquamatrix, Inc. United States
Ardent Pharmaceuticals, Inc. United States
Med Ag Ventures, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 12, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lycera Corp., please visit www.lycera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.